Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer

NCT01650506 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT01650506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01650506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of Erlotinib and Metformin in Triple Negative Breast Cancer
Lead sponsor
Columbia University
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2012
Completion date
June 30, 2016
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer